STOCK TITAN
  1. Home
  2. News
  3. TARS

Tarsus Pharmaceuticals Inc - TARS STOCK NEWS

Welcome to our dedicated news page for Tarsus Pharmaceuticals (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tarsus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tarsus Pharmaceuticals's position in the market.

News
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. secures $200 million financing commitment from Pharmakon Advisors, LP to strengthen its financial position. The company draws $75 million initially with the remaining $125 million available in tranches. The new five-year credit facility bears interest at SOFR plus 6.75% per annum. Pharmakon Advisors is a leading investor in non-dilutive debt for the life sciences industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Tarsus to Participate at Upcoming Investor Conferences
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. (TARS) announces participation in upcoming conferences to discuss advancements in eye care. Key executives will engage in fireside chats and one-on-one meetings to showcase the company's commitment to revolutionizing patient treatment through science and technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences
-
News
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Rhea-AI Summary
TARS launches a creative and impactful consumer education campaign to enhance brand awareness and customer engagement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
none
News
Tarsus Announces Pricing of $100.0 Million Public Offering
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. announces the pricing of an underwritten public offering, including common stock and pre-funded warrants, with expected gross proceeds of approximately $100.0 million. The offering is led by joint book-running managers Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC, and Oppenheimer & Co.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
offering
-
News
Tarsus Announces Proposed $100.0 Million Public Offering
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. announces a $100.0 million public offering of common stock to fund further development, with underwriters including Goldman Sachs and BofA Securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
offering
-
News
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced the launch of XDEMVY® for Demodex blepharitis, achieving $13.1 million in net product sales in Q4 and $14.7 million in the first four months. Positive proof-of-concept results were reported, with significant progress in the clinical portfolio. Financially, Q4 revenues reached $13.1 million, with a net loss of $41.9 million. Full-year 2023 saw total revenues of $17.4 million, with a net loss of $135.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.28%
Tags
earnings
News
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
Rhea-AI Summary
Tarsus Pharmaceuticals (NASDAQ: TARS) announced positive results from the Phase 2a Carpo trial evaluating TP-05 for Lyme disease prevention. Both high and low doses of TP-05 showed significant tick mortality compared to placebo, potentially revolutionizing disease prophylaxis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.68%
Tags
clinical trial
-
News
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will host a live webcast to report Q4 and full year 2023 financial results and provide a corporate update, focusing on revolutionizing treatment for patients starting with eye care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
conferences earnings
-
News
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. CEO Bobak Azamian, M.D., Ph.D., will participate in an in-person fireside chat at the Sixth Annual Guggenheim Healthcare Talks conference in New York City on February 8, 2024. The live webcast of the chat will be available on the TARS website, with replays accessible within 48 hours and archived for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
conferences
News
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced topline results from the Ersa Phase 2a clinical trial evaluating TP-03 for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites. TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
clinical trial
Stock TARS logo
Tarsus Pharmaceuticals Inc

Nasdaq:TARS

TARS Rankings

#2269 Ranked by Market Cap
#3621 Ranked by Stock Gains
N/A Ranked by Dividends

TARS Stock Data

1.36B
24.39M
4.26%
90.03%
20.93%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Irvine

About TARS

tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.